Armaviscon Chondro 3 ml

– for symptomatic treatment of mild, moderate or severe osteoarthritis;
– to increase joint mobility and relieve pain caused by degenerative-dystrophic or post-traumatic joint changes;
– for rehabilitation after arthroscopy;
– for treatment of patients with increased physical activity and who regularly load the affected joint.

Active ingredient

Composition

Contents per 1 ml: chondroitin sulfate sodium – 30.0 mg, sodium hyaluronate – 20.0 mg, sodium citrate dihydrate – 8.63 mg, anhydrous citric acid – 4.89 mg, sodium chloride – 2.1 mg, 10 M sodium hydroxide solution – to pH 6.4-7.6, water for injection – to 1 ml.

How to take, the dosage

Intra-articular. Armaviscon® Chondro is injected into the joint in a volume depending on the size of the joint. The joint cavity should not be overloaded. Up to 2 injections are recommended. Usually a 21G needle is used for the knee joint, for other joints the recommended needle size is 17G to 22G, depending on the joint.
The solution should only be administered by specially trained medical personnel in aseptic conditions in medical institutions. Local anesthetics may be used prior to intra-articular injection, such as subcutaneous lidocaine.
The injection site should be properly disinfected. Disinfectants containing quaternary ammonium compounds should not be used as hyaluronic acid precipitates in the presence of these substances.
The mode of injection into hip and other joints is determined individually by the doctor taking into account the severity of degenerative or traumatic changes in the joint. It is recommended to inject into hip and other joints under ultrasound or fluoroscopic control. The solution should be injected accurately into the joint cavity according to standard methods, taking into account the anatomical features. The effusion from the joint sac should be removed before the solution is injected. The same needle once inserted before aspiration can be used to remove the effusion and to inject the solution. A syringe containing the solution is attached to the needle that has been freed from the syringe. The available amount of synovial fluid should be aspirated to confirm the presence of the needle in the joint cavity before slow insertion. Aseptics and antiseptics should be observed during the procedure. Injection of the solution into the joint cavity should be stopped if pain occurs during the injection. Local anaesthesia is recommended for needle insertion, especially for injections into the hip joint. Avoid the introduction of air into the syringe.
Syringe handling procedures
1. Open the syringe barrel/package under aseptic conditions.
2. Unscrew the cap from the tip of the syringe (the cap is tightly fitted).
3. Squeeze air out through the syringe tip by holding the barrel with one hand and gently pressing the piston rod with the other hand. Take care not to squirt the solution.
4. Attach the needle firmly to the syringe. Screw the needle onto the syringe until it is threaded and firmly seated.
5. Visually check that the needle is threaded all the way.
6. Remove the cap from the needle in a straight motion.
Squeeze out the remaining air from the system by holding the syringe barrel with one hand and gently pressing the piston rod with the other hand until solution appears at the tip of the needle.
The solution should be injected slowly, applying the minimum necessary pressure.
If the needle is blocked, do not increase pressure on the piston rod. Instead, stop injecting and replace the needle.
Each pre-filled syringe is intended for single use. The contents of the syringe should be used slowly after opening.
The solution that is not fully used should not be stored.
Precautionary measures for use
Armaviscon® Chondro should not be used if the package is damaged or opened.
Patients who experience any complications within a few days of injection should contact their physician immediately.

Interaction

Special Instructions

Sodium hyaluronate is obtained by fermentation of the bacteria Streptococcus equi and is carefully purified. However, the physician should consider the potential risk associated with the injection of any biological substances.
During the first 2 days after the procedure it is recommended not to overload the joint, especially avoid prolonged stress.
Armaviscon® Chondro does not affect the ability to drive vehicles, engage in other potentially dangerous activities that require high concentration and speed of psychomotor reactions.
Only for single-use.
The set may include 2 disposable sterile injection needles in order to enable the doctor to choose the needle of a required caliber/size depending on the joint into which the solution will be injected.
Be sure to pay attention to the expiration date on the needle label.
For safe use and disposal of used needles, follow national and regional rules and regulations.

Contraindications

– Hypersensitivity to the components of the product;
– Presence of active inflammatory or infectious processes in the joint;
– Presence of infection or lesions or signs of active skin disease in the area to be injected;
– use in patients diagnosed with autoimmune disease or undergoing immunotherapy;
– acute synovitis;
– pregnancy and lactation;
– under 18 years of age.

Side effects

Pregnancy use

Similarities